Show simple item record

AuthorLaith J., Abu-Raddad
AuthorChemaitelly, Hiam
AuthorCoyle, Peter
AuthorMalek, Joel A.
AuthorAhmed, Ayeda A.
AuthorMohamoud, Yasmin A.
AuthorYounuskunju, Shameem
AuthorAyoub, Houssein H.
AuthorAl Kanaani, Zaina
AuthorAl Kuwari, Einas
AuthorButt, Adeel A.
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar Hassan
AuthorLatif, Ali Nizar
AuthorShaik, Riyazuddin Mohammad
AuthorAbdul Rahim, Hanan F.
AuthorNasrallah, Gheyath K.
AuthorYassine, Hadi M.
AuthorAl Kuwari, Mohamed Ghaith
AuthorAl Romaihi, Hamad Eid
AuthorAl-Thani, Mohamed H.
AuthorAl Khal, Abdullatif
AuthorBertollini, Roberto
Available date2021-10-20T08:40:34Z
Publication Date2021-05-31
Publication NameEClinicalMedicine
Identifierhttp://dx.doi.org/10.1016/j.eclinm.2021.100861
CitationAbu-Raddad, L. J., Chemaitelly, H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., ... & Bertollini, R. (2021). SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine, 35, 100861.
ISSN25895370
URIhttps://www.sciencedirect.com/science/article/pii/S2589537021001413
URIhttp://hdl.handle.net/10576/24583
AbstractBackground Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar. MethodsAll SARS-CoV-2 antibody-positive persons from April 16 to December 31, 2020 with a PCR-positive swab ≥14 days after the first-positive antibody test were investigated for evidence of reinfection. Viral genome sequencing was conducted for paired viral specimens to confirm reinfection. Incidence of reinfection was compared to incidence of infection in the complement cohort of those who were antibody-negative. FindingsAmong 43,044 antibody-positive persons who were followed for a median of 16.3 weeks (range: 0–34.6), 314 individuals (0.7%) had at least one PCR positive swab ≥14 days after the first-positive antibody test. Of these individuals, 129 (41.1%) had supporting epidemiological evidence for reinfection. Reinfection was next investigated using viral genome sequencing. Applying the viral-genome-sequencing confirmation rate, the incidence rate of reinfection was estimated at 0.66 per 10,000 person-weeks (95% CI: 0.56–0.78). Incidence rate of reinfection versus month of follow-up did not show any evidence of waning of immunity for over seven months of follow-up. Meanwhile, in the complement cohort of 149,923 antibody-negative persons followed for a median of 17.0 weeks (range: 0–45.6), incidence rate of infection was estimated at 13.69 per 10,000 person-weeks (95% CI: 13.22–14.14). Efficacy of natural infection against reinfection was estimated at 95.2% (95% CI: 94.1–96.0%). Reinfections were less severe than primary infections. Only one reinfection was severe, two were moderate, and none were critical or fatal. Most reinfections (66.7%) were diagnosed incidentally through random or routine testing, or through contact tracing. InterpretationReinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months. FundingBiomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Genomics Core, all at Weill Cornell Medicine-Qatar, the Ministry of Public Health, Hamad Medical Corporation, and the Qatar Genome Programme.
SponsorThe authors are grateful for support from the Biomedical Research Program, the Biostatistics, Epidemiology, and Biomathematics Research Core, and the Genomics Core, all at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health and Hamad Medical Corporation. The authors are also grateful for support from the Qatar Genome Programme for supporting the viral genome sequencing. The statements made herein are solely the responsibility of the authors.
Languageen
PublisherElsevier
SubjectSARS-CoV-2
Epidemiology
Reinfection
Immunity
Genetics
TitleSARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
TypeArticle
Volume Number35
Open Access user License http://creativecommons.org/licenses/by/4.0/
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record